Revenue
2021
2022
2023
2024
2025
BioStem Technologies, Inc. (BSEM)
Price$3.67Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $47.5M | $69.7M | $16.7M | $6.9M | $4.3M |
| Gross profit | $44.4M | $55.9M | $15.4M | $6.0M | $2.9M |
| Gross margin | 93.59% | 80.27% | 92.45% | 87.17% | 66.03% |
| Research & development | $7.1M | $1.9M | $341,996 | $224,775 | $119,647 |
| Operating expenses | $45.1M | $24.8M | $23.2M | $10.7M | $4.5M |
| Operating income | −$689,147 | $31.1M | −$7.8M | −$4.7M | −$1.6M |
| Operating margin | −1.45% | 44.68% | −46.62% | −68.09% | −36.99% |
| EBITDA | — | $31.5M | −$7.6M | −$6.5M | −$601,995 |
| EBITDA margin | — | 45.21% | −45.27% | −94.84% | −13.87% |
| Net income | $0 | $0 | −$8.5M | −$7.2M | −$1.4M |
| Net profit margin | 0.00% | 0.00% | −50.84% | −104.62% | −33.30% |
| Basic EPSper basic share | — | $1.95 | -$0.62 | -$0.63 | -$0.12 |
| Diluted EPSper diluted share | -$0.39 | $1.43 | -$0.62 | -$0.63 | -$0.12 |
Owners
Reported shareholders
Insider buys & sells
Community posts
BioStem secures access to a $40 million equity-purchase facility
BioStem ($BSEM) Technologies entered into a committed equity facility providing potential access to as much as $40 million through share sales to Roth Principal Investments. The company controls whether to draw on the arrangement and intend ...
